On December 30, 2024, Novavax CZ a.s., a subsidiary of Novavax Inc., finalized the sale of its biologics manufacturing campus in Bohumil, Jevany, Czech Republic to Novo Nordisk Production Czech s.r.o. for $200 million. The transaction, announced on December 3, 2024, included the transfer of properties, moveable assets, equipment, related contracts, and certain employees.The purchaser paid $180 million at closing, following a $10 million initial payment in September 2024. An additional $10 million was placed in escrow, to be released after 12 months, subject to potential claims. Novavax also received approximately $2.6 million as reimbursement for operational costs incurred between the announcement and completion of the sale.This strategic move aligns with Novavax's asset optimization efforts. The company expects to provide further details in its upcoming Annual Report on Form 10-K for the year ending December 31, 2024.

On December 30, 2024, Novavax CZ a.s., a subsidiary of Novavax Inc., finalized the sale of its biologics manufacturing campus in Bohumil, Jevany, Czech Republic to Novo Nordisk Production Czech s.r.o. for $200 million. The transaction, announced on December 3, 2024, included the transfer of properties, moveable assets, equipment, related contracts, and certain employees.The purchaser paid $180 million at closing, following a $10 million initial payment in September 2024. An additional $10 million was placed in escrow, to be released after 12 months, subject to potential claims. Novavax also received approximately $2.6 million as reimbursement for operational costs incurred between the announcement and completion of the sale.This strategic move aligns with Novavax's asset optimization efforts. The company expects to provide further details in its upcoming Annual Report on Form 10-K for the year ending December 31, 2024.